MedTrace Logo

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 825

Last updated 2026-04-28

No results posted yet for this study

Summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Conditions

  • Unresectable Pleural Mesothelioma

Interventions

DRUG

Volrustomig

MEDI5752: Administered as IV infusion

DRUG

Pemetrexed

Alimta: Administered as IV infusion

DRUG

Carboplatin

Paraplatin: Administered as IV infusion

DRUG

Cisplatin

Platinol: Administered as IV infusion

DRUG

Nivolumab

Opdivo: Administered as IV infusion

DRUG

Ipilimumab

Yervoy: Administered as IV infusion

Sponsors & Collaborators

Principal Investigators

  • Marjorie G Zauderer, MD · Memorial Slone Kettering (MSK) Cancer Centre

  • Arnaud Scherpereel, MD · Lille University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2027-11-19
Completion
2028-11-16
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Denmark
  • France
  • Germany
  • Italy
  • Japan
  • Netherlands
  • Norway
  • Poland
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097728 on ClinicalTrials.gov